FSD Pharma Inc. Announces Results of the Annual General & Special Meeting of Shareholders – Nominees of the Concerned Share...
May 17 2021 - 3:18AM
Business Wire
FSD Pharma Inc. (Nasdaq: HUGE) (CSE:HUGE) (FRA:0K9) (the
“Company” or “FSD”) is pleased to announce the
results of its annual general and special meeting of the
shareholders held on May 14th, 2021 (the “Meeting”) at which
54.17% of the votes attached to the issued and outstanding Class B
Subordinate Voting Shares (“Class B Shares”) and Class A
Multiple Voting Shares (“Class A Shares”) were represented.
The board of directors of FSD (the “Board”) was fixed at
seven directors. Each of the nominees of the group of concerned
shareholders led by Messrs. Anthony Durkacz and Zeeshan Saeed (the
“Concerned Shareholders”) were elected to the Board, in
addition to Messrs. Frank Lavelle and Donal Carroll, to hold office
for the ensuing year. However, following his election, Mr. Lavelle
communicated his resignation to the Board.
As a result, Anthony Durkacz, Zeeshan Saeed, Nitin Kaushal,
Lawrence (Larry) Latowsky, Fernando Cugliari and Donal Carroll
shall serve as directors of the Company until the next annual
general meeting of shareholders or until they otherwise cease to
hold office. Full details and backgrounds regarding each of the
directors is included in the information circular of the Concerned
Shareholders dated April 24, 2021, which was filed on the Company’s
SEDAR profile at www.sedar.com.
Anthony Durkacz and Zeeshan Saeed commented, “We are pleased to
see that FSD shareholders have shown their overwhelming support for
the Concerned Shareholders and the Concerned Shareholders’
nominees. We look forward to restoring FSD and know there is a lot
of work ahead of us. We would like to thank all shareholders for
their patience and support.”
In addition, shareholders of the Company: rejected a special
resolution to reorganize the share capital of the Company and
convert the issued and outstanding Class A Shares into Class B
Shares; approved an ordinary resolution to reappoint MNP LLP as the
auditor of the Company for the ensuing year and authorize the
directors of the Company to set the auditor’s remuneration;
approved a special resolution to change the registered office of
the Company from Durham Region, Ontario to a location in the City
of Toronto, Ontario; and approved an ordinary resolution ratifying
the adoption of the Amended and Restated By-law No. 1 of the
Company.
At a meeting of the Board following the Meeting, Anthony Durkacz
and Zeeshan Saeed were appointed Executive Co-Chairmen of the
Board.
About FSD Pharma
FSD Pharma Inc. (www.fsdpharma.com) is a publicly-traded holding
company.
FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty
biotech pharmaceutical R&D company focused on developing
multiple applications of its lead compound, ultramicro PEA by
down-regulating the cytokines to effectuate an anti-inflammatory
response.
Forward Looking Information
Certain statement contained herein are “forward-looking
statements”. Often, but not always, forward-looking statement can
be identified by the use of words such as “plans”, “expects”,
“expected”, “scheduled”, “estimates”, “intends”, “anticipates” or
“believes”, or variations of such words and phrases, or states that
certain actions, events or results “may”, “could”, “would”, “might”
or “will” be taken, occur or be achieved. Forward-looking
statements contained in this press release include the statement
made by Anthony Durkacz regarding FSD. FSD cannot give any
assurance that such forward-looking statements will prove to have
been correct. The reader is cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210517005319/en/
Anthony Durkacz adurkacz@fsdpharma.com
Zeeshan Saeed zsaeed@fsdpharma.com
FSD Pharma (NASDAQ:HUGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
FSD Pharma (NASDAQ:HUGE)
Historical Stock Chart
From Sep 2023 to Sep 2024